{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:10:01Z","timestamp":1777637401055,"version":"3.51.4"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,1,8]],"date-time":"2010-01-08T00:00:00Z","timestamp":1262908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Children with high\u2010risk hepatoblastoma (metastatic disease or a low alpha\u2010fetoprotein at presentation) and those with recurrent disease have an extremely poor prognosis and are in need of novel therapeutic agents and strategies. We describe three patients who were treated with irinotecan (two in combination with vincristine). In two patients, this contributed to a clinical remission. All three patients received a 1\u2010 to 2\u2010year course of irinotecan as maintenance therapy and all remain disease free. Treatment was well tolerated with minimal toxicity. Further evaluation of the use of irinotecan as maintenance therapy in high\u2010risk and recurrent HB patients is warranted. Pediatr Blood Cancer 2010;54:761\u2013763. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/pbc.22408","type":"journal-article","created":{"date-parts":[[2010,1,8]],"date-time":"2010-01-08T23:19:51Z","timestamp":1262992791000},"page":"761-763","source":"Crossref","is-referenced-by-count":25,"title":["Irinotecan as maintenance therapy in high\u2010risk hepatoblastoma"],"prefix":"10.1002","volume":"54","author":[{"given":"Muna","family":"Qayed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christie","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Haugen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard M.","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,4]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2665"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.22.3819"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.400"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7204"},{"key":"e_1_2_4_6_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/jco.2009.27.15_suppl.10017","article-title":"Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium Study","volume":"27","author":"Wagner LM","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200212000-00014"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0173-6"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0096"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686188"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1815"},{"key":"e_1_2_4_12_2","first-page":"32","article-title":"A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group Study","volume":"7","author":"Blaney S","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21629"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6103"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.10013"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.5918"},{"key":"e_1_2_4_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2847"},{"key":"e_1_2_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21280"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22408","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:32:16Z","timestamp":1697675536000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,4]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1002\/pbc.22408"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22408","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,4]]}}}